Salman Ahmed1, Cameron T Nutt2, Nwamaka D Eneanya3, Peter P Reese3, Karthik Sivashanker4,5, Michelle Morse2,6,7, Thomas Sequist2,8, Mallika L Mendu9,5,10. 1. Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. sahmed28@bwh.harvard.edu. 2. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Diversity, Inclusion, and Experience, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Quality and Safety, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. EqualHealth, Tabarre, Haiti. 7. EqualHealth, Brookline, MA, USA. 8. Department of Quality, Patient Experience and Equity, Partners HealthCare, Boston, MA, USA. 9. Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 10. Center for Population Health, Partners HealthCare, Boston, MA, USA.
Abstract
BACKGROUND: Advancing health equity entails reducing disparities in care. African-American patients with chronic kidney disease (CKD) have poorer outcomes, including dialysis access placement and transplantation. Estimated glomerular filtration rate (eGFR) equations, which assign higher eGFR values to African-American patients, may be a mechanism for inequitable outcomes. Electronic health record-based registries enable population-based examination of care across racial groups. OBJECTIVE: To examine the impact of the race multiplier for African-Americans in the CKD-EPI eGFR equation on CKD classification and care delivery. DESIGN: Cross-sectional study SETTING: Two large academic medical centers and affiliated community primary care and specialty practices. PARTICIPANTS: A total of 56,845 patients in the Partners HealthCare System CKD registry in June 2019, among whom 2225 (3.9%) were African-American. MEASUREMENTS: Exposures included race, age, sex, comorbidities, and eGFR. Outcomes were transplant referral and dialysis access placement. RESULTS: Of 2225 African-American patients, 743 (33.4%) would hypothetically be reclassified to a more severe CKD stage if the race multiplier were removed from the CKD-EPI equation. Similarly, 167 of 687 (24.3%) would be reclassified from stage 3B to stage 4. Finally, 64 of 2069 patients (3.1%) would be reassigned from eGFR > 20 ml/min/1.73 m2 to eGFR ≤ 20 ml/min/1.73 m2, meeting the criterion for accumulating kidney transplant priority. Zero of 64 African-American patients with an eGFR ≤ 20 ml/min/1.73 m2 after the race multiplier was removed were referred, evaluated, or waitlisted for kidney transplant, compared to 19.2% of African-American patients with eGFR ≤ 20 ml/min/1.73 m2 with the default CKD-EPI equation. LIMITATIONS: Single healthcare system in the Northeastern United States and relatively small African-American patient cohort may limit generalizability. CONCLUSIONS: Our study reveals a meaningful impact of race-adjusted eGFR on the care provided to the African-American CKD patient population.
BACKGROUND: Advancing health equity entails reducing disparities in care. African-American patients with chronic kidney disease (CKD) have poorer outcomes, including dialysis access placement and transplantation. Estimated glomerular filtration rate (eGFR) equations, which assign higher eGFR values to African-American patients, may be a mechanism for inequitable outcomes. Electronic health record-based registries enable population-based examination of care across racial groups. OBJECTIVE: To examine the impact of the race multiplier for African-Americans in the CKD-EPI eGFR equation on CKD classification and care delivery. DESIGN: Cross-sectional study SETTING: Two large academic medical centers and affiliated community primary care and specialty practices. PARTICIPANTS: A total of 56,845 patients in the Partners HealthCare System CKD registry in June 2019, among whom 2225 (3.9%) were African-American. MEASUREMENTS: Exposures included race, age, sex, comorbidities, and eGFR. Outcomes were transplant referral and dialysis access placement. RESULTS: Of 2225 African-American patients, 743 (33.4%) would hypothetically be reclassified to a more severe CKD stage if the race multiplier were removed from the CKD-EPI equation. Similarly, 167 of 687 (24.3%) would be reclassified from stage 3B to stage 4. Finally, 64 of 2069 patients (3.1%) would be reassigned from eGFR > 20 ml/min/1.73 m2 to eGFR ≤ 20 ml/min/1.73 m2, meeting the criterion for accumulating kidney transplant priority. Zero of 64 African-American patients with an eGFR ≤ 20 ml/min/1.73 m2 after the race multiplier was removed were referred, evaluated, or waitlisted for kidney transplant, compared to 19.2% of African-American patients with eGFR ≤ 20 ml/min/1.73 m2 with the default CKD-EPI equation. LIMITATIONS: Single healthcare system in the Northeastern United States and relatively small African-American patient cohort may limit generalizability. CONCLUSIONS: Our study reveals a meaningful impact of race-adjusted eGFR on the care provided to the African-American CKD patient population.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Tanjala S Purnell; Xun Luo; Lisa A Cooper; Allan B Massie; Lauren M Kucirka; Macey L Henderson; Elisa J Gordon; Deidra C Crews; L Ebony Boulware; Dorry L Segev Journal: JAMA Date: 2018-01-02 Impact factor: 56.272
Authors: Carmen A Peralta; Neil Risch; Feng Lin; Michael G Shlipak; Alex Reiner; Elad Ziv; Hua Tang; David Siscovick; Kirsten Bibbins-Domingo Journal: Am J Nephrol Date: 2009-12-21 Impact factor: 3.754
Authors: Kimberly Harding; Tesfaye B Mersha; Joseph A Vassalotti; Fern A Webb; Susanne B Nicholas Journal: Am J Nephrol Date: 2017-08-05 Impact factor: 4.605
Authors: Dinushika Mohottige; L Ebony Boulware; Chandra L Ford; Camara Jones; Keith C Norris Journal: Clin J Am Soc Nephrol Date: 2021-11-17 Impact factor: 8.237
Authors: Jeffrey A Sparks; Kathleen M M Vanni; Matthew A Sparks; Chang Xu; Leah M Santacroce; Robert J Glynn; Paul M Ridker; Daniel H Solomon Journal: J Am Soc Nephrol Date: 2021-09-22 Impact factor: 10.121
Authors: Chi-Yuan Hsu; Wei Yang; Rishi V Parikh; Amanda H Anderson; Teresa K Chen; Debbie L Cohen; Jiang He; Madhumita J Mohanty; James P Lash; Katherine T Mills; Anthony N Muiru; Afshin Parsa; Milda R Saunders; Tariq Shafi; Raymond R Townsend; Sushrut S Waikar; Jianqiao Wang; Myles Wolf; Thida C Tan; Harold I Feldman; Alan S Go Journal: N Engl J Med Date: 2021-09-23 Impact factor: 91.245
Authors: Cynthia Delgado; Mukta Baweja; Deidra C Crews; Nwamaka D Eneanya; Crystal A Gadegbeku; Lesley A Inker; Mallika L Mendu; W Greg Miller; Marva M Moxey-Mims; Glenda V Roberts; Wendy L St Peter; Curtis Warfield; Neil R Powe Journal: J Am Soc Nephrol Date: 2021-09-23 Impact factor: 10.121
Authors: Jeffrey L Jackson; Carol Bates; Steven M Asch; Rachel Roberts; Jenni R Clarkson Journal: J Gen Intern Med Date: 2021-08-13 Impact factor: 6.473
Authors: Lesley A Inker; Nwamaka D Eneanya; Josef Coresh; Hocine Tighiouart; Dan Wang; Yingying Sang; Deidra C Crews; Alessandro Doria; Michelle M Estrella; Marc Froissart; Morgan E Grams; Tom Greene; Anders Grubb; Vilmundur Gudnason; Orlando M Gutiérrez; Roberto Kalil; Amy B Karger; Michael Mauer; Gerjan Navis; Robert G Nelson; Emilio D Poggio; Roger Rodby; Peter Rossing; Andrew D Rule; Elizabeth Selvin; Jesse C Seegmiller; Michael G Shlipak; Vicente E Torres; Wei Yang; Shoshana H Ballew; Sara J Couture; Neil R Powe; Andrew S Levey Journal: N Engl J Med Date: 2021-09-23 Impact factor: 176.079